AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31028006 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention targeting healthful diet and physical activity
Number of subjects: 18
Study 31028006 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control targeting sexual risk behaviors
Number of subjects: 18
Study 31028006 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 18
Study 28035924 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day) plus Choline Alphoscerate (1200 mg/day)
Number of subjects: 113
Study 28035924 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (10 mg/day) plus Placebo
Number of subjects: 113
Study 26310362 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Treatment Condition (ATC)
Number of subjects: 59
Study 26310362 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Condition (WLC)
Number of subjects: 59
Study 23806882 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 84
Study 23806882 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (SEVO) anesthesia
Number of subjects: 84
Study 20932707 — intervention group
Group type: COMPARATOR
Intervention: ACL-PCL
Number of subjects: 440
Study 20932707 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 440
Study 20932707 — intervention group
Group type: COMPARATOR
Intervention: PS
Number of subjects: 440
Study 19514089 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF 50 microg/mL
Number of subjects: 113
Study 19514089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 17543813 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine as a bolus and/or 50‐hour infusion
Number of subjects: 233
Study 17543813 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 233
Study 15877015 — intervention group
Group type: EXPERIMENTAL
Intervention: 61% alcohol-ZPT product (waterless application)
Number of subjects: 49
Study 15877015 — intervention group
Group type: EXPERIMENTAL
Intervention: 61% alcohol-ZPT product (water-aided application)
Number of subjects: 49
Study 15877015 — intervention group
Group type: COMPARATOR
Intervention: Commonly available handwashes (control)
Number of subjects: 49
Study 12830748 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education during waiting time in the clinic (n = 104)
Number of subjects: 205
Study 12830748 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 101)
Number of subjects: 205
Study 15168718 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) plus Didanosine (ddI)
Number of subjects: 3
Study 15168718 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) plus Lamivudine (3TC)
Number of subjects: 3
Study 15168718 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) plus Didanosine (ddI)
Number of subjects: 3
Study 15168718 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) plus Lamivudine (3TC)
Number of subjects: 3
Study 8573702 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of eye movements treatment (wearing glasses providing a reminder bleep if patients failed to move their eyes to the left in a 15 s interval) for 2 h 40 min a week for 4 weeks.
Number of subjects: 18
Study 8573702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for visual inattention).
Number of subjects: 18
Study 2677240 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine 150 mg/day
Number of subjects: 124
Study 2677240 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (25 mg bid, 50 mg bid, 75 mg bid)
Number of subjects: 124
Study 2677240 — intervention group
Group type: COMPARATOR
Intervention: Tranylcypromine 20 mg/day
Number of subjects: 124
Study 2677240 — intervention group
Group type: COMPARATOR
Intervention: Nomifensine 100 mg/day
Number of subjects: 124
Study 860894 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride (N = 22)
Number of subjects: 41
Study 860894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride (N = 19)
Number of subjects: 41
Study 31025876 — intervention group
Group type: EXPERIMENTAL
Intervention: T-4°C-15 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: EXPERIMENTAL
Intervention: T-4°C-30 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: EXPERIMENTAL
Intervention: T-4°C-60 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: EXPERIMENTAL
Intervention: T-4°C-120 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: EXPERIMENTAL
Intervention: T-24°C-15 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: EXPERIMENTAL
Intervention: T-24°C-30 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: EXPERIMENTAL
Intervention: T-24°C-60 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: EXPERIMENTAL
Intervention: T-24°C-120 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: COMPARATOR
Intervention: AN-4°C-15 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: COMPARATOR
Intervention: AN-4°C-30 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: COMPARATOR
Intervention: AN-4°C-60 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: COMPARATOR
Intervention: AN-4°C-120 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: COMPARATOR
Intervention: AN-24°C-15 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: COMPARATOR
Intervention: AN-24°C-30 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: COMPARATOR
Intervention: AN-24°C-60 minutes
Number of subjects: 50
Study 31025876 — intervention group
Group type: COMPARATOR
Intervention: AN-24°C-120 minutes
Number of subjects: 50
Study 28575885 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 88
Study 28575885 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 88
Study 25050869 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipin (5-10 mg/d)
Number of subjects: 41
Study 25050869 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (120-240 mg/d)
Number of subjects: 41
Study 23556460 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic (GA)
Number of subjects: 52
Study 23556460 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (PSY)
Number of subjects: 52
Study 23556460 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC)
Number of subjects: 52
Study 23556460 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber supplements (GA, PSY, CMC)
Number of subjects: 52
Study 23556460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21931737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) rAd5 vaccine boost
Number of subjects: 90
Study 21931737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) rAd5 vaccine boost
Number of subjects: 90
Study 21931737 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rAd5 vaccine boost
Number of subjects: 90
Study 21931737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving rAd5 vaccine boost)
Number of subjects: 90
Study 18348715 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free vegan diet
Number of subjects: 66
Study 18348715 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 66
Study 18348715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet (responders)
Number of subjects: 66
Study 17240799 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (radiotherapy plus injection cisplatin 30 mg/m2 once weekly for 5 weeks)
Number of subjects: 160
Study 17240799 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (external radiotherapy of 5000 cGy in conventional fractionation followed by brachytherapy)
Number of subjects: 160
Study 17240799 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 160
Study 17240799 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 160
Study 12788885 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg DHEA after 4 days of dexamethasone (Dex; 4 x 0.5 mg/d)
Number of subjects: 16
Study 12788885 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (Dex; 4 x 0.5 mg/d)
Number of subjects: 16
Study 12788885 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 4 days of dexamethasone (Dex; 4 x 0.5 mg/d)
Number of subjects: 16
Study 12788885 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 16
Study 11004057 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/d)
Number of subjects: 19
Study 11004057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8972377 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline injection (0.5 ml of balanced salt solution) for conjunctival wound closure (Group B)
Number of subjects: 40
Study 8972377 — intervention group
Group type: COMPARATOR
Intervention: Manual closure with Moorfields forceps (Group A)
Number of subjects: 40
Study 8972377 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline injection (Group B)
Number of subjects: 40
Study 1358607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg three times daily
Number of subjects: 0
Study 1358607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg three times daily
Number of subjects: 0
Study 1358607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4089582 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol (10 mg/d, n = 14)
Number of subjects: 30
Study 4089582 — intervention group
Group type: EXPERIMENTAL
Intervention: methyldopa (250 mg/d, n = 16)
Number of subjects: 30
Study 4089582 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (25 mg/d) and amiloride (2.5 mg/d)
Number of subjects: 30
Study 29277138 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (reading a brief informational pamphlet about ECT)
Number of subjects: 91
Study 29277138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 91
Study 27138833 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral rTMS (10 Hz left DLPFC, 1 Hz right DLPFC)
Number of subjects: 30
Study 27138833 — intervention group
Group type: COMPARATOR
Intervention: Unilateral rTMS (1 Hz right DLPFC)
Number of subjects: 30
Study 27138833 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral rTMS
Number of subjects: 30
Study 27138833 — intervention group
Group type: COMPARATOR
Intervention: Unilateral rTMS
Number of subjects: 30
Study 24463948 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD (DVD format + standard care)
Number of subjects: 84
Study 24463948 — intervention group
Group type: COMPARATOR
Intervention: Standard care (written anticipatory guidance handout and free talk)
Number of subjects: 84
Study 24463948 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD group
Number of subjects: 84
Study 24463948 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 84
Study 22683613 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor plus granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study 22683613 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study 20236777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 0
Study 18377160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sister‐to‐Sister intervention
Number of subjects: 0
Study 18377160 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16124423 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate (initial dose of 40 mg/kg bodyweight, in 3 or 4 divided doses in the first 24 hours, followed by 10 mg/kg bodyweight once daily for three consecutive days)
Number of subjects: 13
Study 16124423 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate
Number of subjects: 13
Study 16124423 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal artesunate (high initial dose regimen of 20 mg/kg bodyweight)
Number of subjects: 13
Study 15311661 — intervention group
Group type: EXPERIMENTAL
Intervention: Using rigid finger sheath
Number of subjects: 0
Study 15311661 — intervention group
Group type: EXPERIMENTAL
Intervention: Using rigid probe
Number of subjects: 0
Study 15311661 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing the number of end effectors
Number of subjects: 0
Study 15311661 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a compliant finger cover
Number of subjects: 0
Study 15311661 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting the fingers
Number of subjects: 0
Study 10783940 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and self-management plan
Number of subjects: 140
Study 9269055 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine
Number of subjects: 0
Study 9269055 — intervention group
Group type: COMPARATOR
Intervention: Annual influenza vaccinations
Number of subjects: 0
Study 8334064 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 63
Study 8334064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of atenolol 50 mg and nifedipine retard 20 mg (Tenif) once daily
Number of subjects: 63
Study 8334064 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg daily
Number of subjects: 63
Study 3769183 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde coronary sinus perfusion
Number of subjects: 40
Study 3769183 — intervention group
Group type: COMPARATOR
Intervention: Anterograde aortic root perfusion
Number of subjects: 40
Study 29775957 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS‐XR (60mg or 80mg daily)
Number of subjects: 126
Study 27132212 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE‐A3 immunotherapeutic
Number of subjects: 2312
Study 27132212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2312
Study 27132212 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE‐A3 immunotherapeutic (no chemotherapy)
Number of subjects: 2312
Study 27132212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no chemotherapy)
Number of subjects: 2312
Study 24304291 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mM Ca-lactate pre-rinse followed by a 905 ppm fluoride rinse
Number of subjects: 9
Study 24304291 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mM Ca-lactate pre-rinse followed by a 905 ppm fluoride rinse
Number of subjects: 9
Study 24304291 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 mM Ca-lactate pre-rinse followed by a 905 ppm fluoride rinse
Number of subjects: 9
Study 24304291 — intervention group
Group type: COMPARATOR
Intervention: 905 ppm fluoride rinse alone
Number of subjects: 9
Study 22276905 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb dependency (lowering the limb from heart level to 30 cm below heart level)
Number of subjects: 34
Study 22276905 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb dependency
Number of subjects: 34
Study 22276905 — intervention group
Group type: COMPARATOR
Intervention: Sympathetic blockade (acute systemic sympathetic blockade)
Number of subjects: 34
Study 20147846 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (AMD)
Number of subjects: 30
Study 20147846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifekalant (NIF)
Number of subjects: 30
Study 19253734 — intervention group
Group type: EXPERIMENTAL
Intervention: External irradiation (25-60 Gy)
Number of subjects: 70
Study 19253734 — intervention group
Group type: COMPARATOR
Intervention: No external irradiation
Number of subjects: 70
Study 16023481 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic diabetic patients with claw/hammer toe deformity
Number of subjects: 26
Study 16023481 — intervention group
Group type: COMPARATOR
Intervention: Neuropathic diabetic controls without deformity
Number of subjects: 26
Study 12538211 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative epidural analgesia
Number of subjects: 915
Study 12538211 — intervention group
Group type: COMPARATOR
Intervention: IV opioids
Number of subjects: 915
Study 12538211 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 915
Study 12538211 — intervention group
Group type: COMPARATOR
Intervention: Control group (IV opioids)
Number of subjects: 915
Study 11778184 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVLX) at a dose of 300 mg/d
Number of subjects: 138
Study 11778184 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (OFLX) at a dose of 600 mg/d
Number of subjects: 138
Study 9017171 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum mouthrinse (500 ppm Al) and placebo dentifrice
Number of subjects: 260
Study 9017171 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum mouthrinse (500 ppm Al) and fluoride dentifrice (1100 ppm F)
Number of subjects: 260
Study 9017171 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse and fluoride dentifrice (1100 ppm F)
Number of subjects: 260
Study 1634661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (140 micrograms/kg per min for 6 min)
Number of subjects: 175
Study 1634661 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress
Number of subjects: 175
Study 1634661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 175
Study 1634661 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 175
Study 6695025 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-gel prostheses
Number of subjects: 37
Study 6695025 — intervention group
Group type: COMPARATOR
Intervention: Saline-filled prostheses
Number of subjects: 37
Study 30888975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure (PP) measurement
Number of subjects: 170
Study 29554282 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 1622
Study 29554282 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin
Number of subjects: 1622
Study 26773719 — intervention group
Group type: EXPERIMENTAL
Intervention: Good fitness level (maximum oxygen uptake > 25th percentile)
Number of subjects: 44
Study 26773719 — intervention group
Group type: COMPARATOR
Intervention: Poor fitness level (maximum oxygen uptake < 25th percentile)
Number of subjects: 44
Study 26773719 — intervention group
Group type: EXPERIMENTAL
Intervention: Good fitness level
Number of subjects: 44
Study 26773719 — intervention group
Group type: COMPARATOR
Intervention: Poor fitness level
Number of subjects: 44
Study 24608457 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 h continuous TCD‐US for MCA
Number of subjects: 42
Study 24608457 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 42
Study 22028294 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized therapy based on ERCC1 and RRM1 expression
Number of subjects: 0
Study 22028294 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Trial A, B, C)
Number of subjects: 0
Study 20112404 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-CT scans in RA patients
Number of subjects: 58
Study 20112404 — intervention group
Group type: COMPARATOR
Intervention: Micro-CT scans in healthy individuals
Number of subjects: 58
Study 18074942 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol plus folic acid (4 g myo-inositol plus 400 mcg folic acid)
Number of subjects: 92
Study 18074942 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 mcg folic acid)
Number of subjects: 92
Study 15610252 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP testing (diagnostic strategy with BNP levels)
Number of subjects: 452
Study 15610252 — intervention group
Group type: COMPARATOR
Intervention: Control group (diagnostic strategy without BNP levels)
Number of subjects: 452
Study 11971941 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 25
Study 10435469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 290
Study 10435469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 290
Study 10435469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 8672312 — intervention group
Group type: COMPARATOR
Intervention: Pregnant normotensive (NPIH)
Number of subjects: 41
Study 8672312 — intervention group
Group type: COMPARATOR
Intervention: Pregnant patients with pregnancy-induced hypertension (PIH)
Number of subjects: 41
Study 8672312 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pregnant (NP)
Number of subjects: 41
Study 2296878 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg twice daily
Number of subjects: 27
Study 2296878 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 60 mg three times daily
Number of subjects: 27
Study 2296878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg three times daily
Number of subjects: 27
Study 370420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 165
Study 370420 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole‐carboxamide
Number of subjects: 165
Study 370420 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine
Number of subjects: 165
Study 370420 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole‐carboxamide followed by cyclophosphamide
Number of subjects: 165
Study 31115273 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCS group (60 participants)
Number of subjects: 60
Study 31115273 — intervention group
Group type: COMPARATOR
Intervention: Recovered mTBI group (30 participants)
Number of subjects: 60
Study 31115273 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (17 participants)
Number of subjects: 60
Study 28394670 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) three times a week for 3 months
Number of subjects: 30
Study 28394670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, normal diet, usual exercise)
Number of subjects: 30
Study 28394670 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 30